论文部分内容阅读
目的探讨TOPOⅡa的表达与蒽环类新辅助化疗的疗效关系及新辅助化疗敏感性的预测指标。方法采用免疫组化的方法检测100例乳腺癌患者化疗前TOPOⅡa的表达情况,并评估其与乳腺癌新辅助化疗疗效的关系。结果100例乳腺癌患者,TOPOⅡa的阳性表达率为47.0%;TOPOⅡa的表达状态与化疗疗效及疗效的程度密切相关(P=0.005;P=0.011)。结论TOPOⅡa过表达的患者能从蒽环类化疗中获取更多的益处;TOPOⅡa可能成为预测蒽环类化疗敏感性的独立预后指标。
Objective To investigate the relationship between the expression of TOPOⅡa and anthracycline neoadjuvant chemotherapy and to predict the sensitivity of neoadjuvant chemotherapy. Methods Immunohistochemical method was used to detect the expression of TOPOⅡa in 100 cases of breast cancer before chemotherapy, and to evaluate its relationship with the efficacy of neoadjuvant chemotherapy in breast cancer. Results The positive expression rate of TOPOⅡa in 100 cases of breast cancer was 47.0%. The expression of TOPOⅡa was closely related to the curative effect and curative effect (P = 0.005; P = 0.011). Conclusions Patients with TOPOⅡa overexpression may get more benefit from anthracycline chemotherapy. TOPOⅡa may be an independent predictor of anthracycline sensitivity.